TPEx-Listed HanchorBio Advances Global Impact of HCB101 Immunotherapy
TAIPEI, SHANGHAI and SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY
Article Date
July 16, 2025
This article is featured on another website.
Go to article
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…